Saw Palmetto Berry Extract

Single-ingredient saw palmetto extract reference formula at 1000 mg per serving, developed as softgels or capsules.

Saw Palmetto is a reference formula for brands building a single-ingredient botanical extract product at a default amount of 1000 mg of saw palmetto extract per serving. The extract is the only active ingredient, so the development work centers on the fatty acid content of the extract, the oily nature of the material, and the choice between a softgel and a powder-filled capsule.

Softgel and capsule are the lead formats, because a lipid-rich berry extract is handled as an oil fill or as a free-flowing extract powder. The reference labels also include powders and whole-berry materials, which are different raw materials, so the page is built around the extract and leaves berry powder to a separate project.

Ingredient Composition

IngredientPer ServingRaw Material FormAlternative Form (same amount of active)
Saw Palmetto1000 mg (default amount)Saw palmetto (Serenoa repens) berry extract, for example the Saw Palmetto Extract Powder grade for capsules or the oil-type extract for softgel fills; specification 1000 mg extract per serving, fatty acid content set by the supplier specificationSaw Palmetto Extract Powder 25% & 45% Fatty Acids when the brand sets a fatty acid grade in the specification

Amounts are stated as mg of saw palmetto extract as purchased, not of fatty acids. The label names the ingredient as saw palmetto extract; the fatty acid content per serving equals the extract weight multiplied by its assay, so the grade is part of the specification and a change of grade changes the fatty acid dose.

Intended Benefits & Formula Rationale

This formula is designed for products positioned around botanical prostate and urinary nutrition for men. Saw palmetto extract is included as the single active so that the extract grade, the amount and the fill system can be set without interaction with other actives.

Intended Benefit DirectionKey IngredientsFormulation Rationale
Botanical prostate nutritionSaw PalmettoIncluded because Serenoa repens is described among the most studied and used medicinal plants for prostate conditions such as benign hypertrophy, prostatitis and chronic pelvic pain syndrome [1]. Evidence: Referenced
Urinary functionSaw PalmettoA meta-analysis of 27 studies of a hexanic Serenoa repens extract at 320 mg daily reported 0.64 fewer voids per night and a higher maximal urinary flow rate than placebo [2], while a Cochrane review of 27 randomized trials with 4656 participants concluded that Serenoa repens alone provides little to no benefit for men with lower urinary tract symptoms due to benign prostatic enlargement [3]. Evidence: Contested

The extract weight is the stated amount, and the extract type and grade decide what that amount contains. The favorable meta-analysis in [2] covers one hexanic extract at 320 mg daily, so amount, extract type and claims are decisions for the brand and its market review.

Available Formats

The saw palmetto reference formula is built for softgel and capsule versions; counts per serving and fill sizes are design choices that the brand can adjust.

FormatUnitPer ServingPack SizeOther Ingredients (typical)Suitability
Softgel1 softgel320 mg extract60 or 90 softgelsGelatin or vegetable shell, glycerin, carrier oil, lecithinLead format; oily extract in an oil fill
Capsule2 capsules1000 mg extract60 or 120 capsulesSilica, magnesium stearate, gelatin or vegetable shellExtract powder fill; carries the 1000 mg example amount

Raw Material Input & Fill (Design Estimate)

Design estimates. The input is the labeled extract weight at an assumed 100% assay of the extract as purchased, so a 1000 mg capsule serving uses 500 mg of extract in each of 2 capsules, and the softgel uses 320 mg per softgel; fatty acid content follows from the grade and is fixed in the specification.

FormatRaw Material Input per UnitDesign FillBalance for ExcipientsVerification Before Scale-Up
Softgel320 mg extract500 mg per softgel180 mgFill viscosity and suspension stability, shell compatibility, seal and leak check, fatty acid assay
Capsule500 mg extract560 mg per capsule60 mgFlow and sticking, fill weight variation, fatty acid assay, moisture

Liquid, tablet and powder-sachet versions are separate projects, because a fatty acid extract needs its own emulsion or compression matrix in those systems.

Formulation Considerations

Oily extract and softgel shell. A fatty acid rich extract is waxy or oily, so the softgel fill is built as a suspension or solution in a carrier oil, and the shell, fill viscosity and seal are checked together for leakage and shell softening during the stability plan.
Extract versus berry powder. One reference label lists 1000 mg as 0.25 teaspoon of powder, and berry powder, extract powder and oil-type extract differ in fatty acid content and fill weight. The page is built around the extract, so a berry powder version is a separate specification and not a substitution of weight.
Extract type and standardization. The trials pooled in [2] used one hexanic extract and excluded other Serenoa repens extracts, so extraction solvent, fatty acid profile and residual solvent limits are written into the specification and a change of supplier or extraction method is a change of the formula.
Market and safety review. Gastrointestinal disorders were the most frequent adverse reaction reported in [2], at a mean incidence of 3.8%. Drug interactions and the labeling statements for men taking prostate or hormone-related medicines are reviewed for each sales market.

Customization Options

Brands adjust the amount, the extract grade, the format and the add-ons.

ParameterRangeNote
Extract per serving160, 320, 450 or 1000 mgOptions for the brand; softgel count or capsule count changes with the amount
Fatty acid gradeSet by the supplier specification, for example 25% or 45%Changes the fatty acid dose per serving and the input weight
FormatSoftgel or capsuleLiquid, tablet and powder are separate projects
Pack size30 to 120 unitsSet by the brand
Add-onsPumpkin seed oil, zinc, lycopeneA second oil changes fill viscosity and shell compatibility, and a mineral or carotenoid changes the specification

The pilot run confirms fill viscosity and suspension stability of the oil blend or flow of the powder fill, shell seal and leak behavior, and the fatty acid assay of the first units against the specification.

Technical Status & Data Sources

ItemStatusDetails
Reference formulaNIH DSLDThe ingredient and amount come from a labeled product in the NIH DSLD (1000 mg on the label of CF032592; example DSLD labels 282585, 287771, 287772). The label names the ingredient as saw palmetto extract; an extract with a fatty acid content set by the supplier specification is set as the form.
SpecificationSet in formulationSerenoa repens berry extract, 1000 mg per serving as the example amount; fatty acid content, extraction solvent, residual solvent, pesticide and heavy-metal limits and method are fixed with the supplier. Unit size, fill weight and stability are set in formulation.
Data sourceNIH DSLDDSLD v9.4.0, downloaded 2026-01-10: 50,824 reference formulas merged from on-market labels with complete ingredient amounts. Counts show how labels are distributed.
Market reviewPer marketDose limits, labeling and claims are reviewed for each sales market before a finished product is developed.
ReferencesSources[1] Cicero AFG, Allkanjari O, Busetto GM, et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl. 2019;91(3). DOI · PubMed<br>[2] Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018;122(6):1049-1065. DOI · PubMed<br>[3] Franco JV, Trivisonno L, Sgarbossa NJ, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database Syst Rev. 2023;6(6):CD001423. DOI · PubMed

Related products

OEM/ODM Development Inquiry

Essencefield supports custom supplement formulation and OEM/ODM development, including ingredient selection, dosage adjustments, delivery formats, flavors, packaging, and commercial supply. Submit your project requirements below to explore customization options, sample development, and manufacturing solutions tailored to your brand and target market.